NEW YORK (GenomeWeb) – Bayer and Leica Biosystems said today they will collaborate on the development of a companion diagnostic that employs immunohistochemistry and RNAscope, a multiplex nucleic acid hybridization technology, to test cancer tissue.

Financial terms of the agreement were not disclosed.

Under the terms of the deal, Leica will provide expertise in assay development, regulatory approval, and commercialization of companion diagnostic tests for targeted anticancer therapies developed by Bayer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.